Case Report

Adrenal and Hepatic Venous Sampling in a Case of Aldosterone-Producing Adrenocortical Carcinoma with Hepatic Metastasis

Toru Sugiyama,1 Yuriko Sasahara,1 Hironobu Sasano,2 and Eri Hayakawa1

1Division of Endocrinology and Metabolism, Japanese Red Cross Musashino Hospital, Tokyo, Japan
2Department of Pathology, Tohoku University School of Medicine, Sendai, Miyagi, Japan

Correspondence should be addressed to Toru Sugiyama; tsugiyama@musashino.jrc.or.jp

Received 20 January 2021; Accepted 8 April 2021; Published 15 April 2021

Copyright © 2021 Toru Sugiyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Adrenocortical carcinoma (ACC) is a rare and highly aggressive malignancy. ACCs often secrete adrenal steroid hormones including cortisol and androgens; however, aldosterone-producing ACC is very rare. Although aldosterone production of aldosterone is assessed by adrenal venous sampling, the use of sampling from the relevant vein to assess aldosterone production from a tumor arising from ACC metastasis has not been previously reported. Case Presentation. We report the case of a 69-year-old Japanese man with aldosterone-producing ACC with hepatic metastasis. He presented with a history of treatment-resistant hypertension and hypokalemia. Endocrinological examination showed markedly increased plasma aldosterone concentration and suppressed plasma renin activity. Serum cortisol concentration was not suppressed by administration of dexamethasone 1 mg, and normal circadian variation of cortisol secretion was disrupted. Abdominal computed tomography showed a large tumor in the left adrenal gland and multiple tumors in the liver. Together, these results strongly suggested ACC with multiple liver metastases causing primary aldosteronism and subclinical Cushing syndrome. Adrenal and hepatic venous sampling showed markedly increased aldosterone concentration in the left adrenal vein but no increase in the hepatic vein, despite a pathological diagnosis of ACC with hepatic metastasis, with immunohistochemical investigation showing both primary and secondary tumors to have synthetic capability for aldosterone. The patient received mitotane but declined combination chemotherapy and died 2 months later. Conclusion. This is the first report of adrenal and hepatic venous sampling in a case of aldosterone-producing ACC with hepatic metastasis. The case suggests that hepatic venous sampling is unable to detect aldosterone production from liver metastases arising from ACC.

1. Introduction

Adrenocortical carcinoma (ACC) is a rare, highly aggressive malignancy with an estimated annual incidence of 0.7–2.0 cases per million population. It has a heterogeneous clinical presentation, and prognosis is generally poor. Approximately 60–70% of ACCs secrete hormones, mostly glucocorticoids or androgens. Less than 10% of hormone-secreting ACCs produce aldosterone, in which cases the excessive production can cause primary aldosteronism [1–3].

Common causes of primary aldosteronism are an aldosterone-producing adenoma or bilateral idiopathic adrenal hyperplasia. The condition frequently results in difficult-to-treat arterial hypertension, sodium retention, and hypokalemia.

In cases of primary aldosteronism, adrenal venous sampling (AVS) is considered the gold standard test for determining whether the excessive aldosterone production is uni- or bilateral and identifying the adrenal gland responsible [4]. However, there have been no reports of the use of sampling from the relevant vein to assess aldosterone production from a tumor arising from ACC metastasis.

Here, we report what we believe to be the first case of aldosterone-producing ACC with hepatic metastasis in which adrenal and hepatic venous sampling were carried out...
to assess the production of aldosterone from the primary and secondary tumor, respectively.

2. Case Presentation

A 69-year-old man with an 8-month history of treatment-resistant hypertension and hypokalemia was referred to our hospital for investigation of suspected secondary hypertension. On physical examination, the only abnormal finding was hypertension (178/105 mmHg); there were no signs of Cushing syndrome (e.g., moon facies, central obesity, and buffalo hump).

Laboratory findings showed hypokalemia (2.3 mEq/L) (Table 1). The results of endocrine examination (Table 2) showed a markedly increased plasma aldosterone concentration (PAC; 1710 μg/mL) and suppressed plasma renin activity (PRA; 0.2 ng/mL/h). Serum DHEA-S (35 μg/dL) was within the normal range (12–133 μg/dL). Fasting plasma concentrations of the adrenocorticotropic hormone (ACTH) and serum cortisol were 2.1 μg/mL (below the lower limit of normal, 7.2 μg/mL) and 9.4 μg/dL (within the normal range, 4.0–18.2 μg/dL), respectively. Serum cortisol concentration was not suppressed in response to an overnight low-dose (1 mg) dexamethasone suppression test, and normal circadian variation of cortisol secretion was disrupted. Both urinary aldosterone concentration and cortisol concentration were increased: 549 μg/24h (normal, <10 μg/24h) and 328 μg/24h (upper limit of normal, 80.3 μg/24h), respectively.

Abdominal computed tomography (CT) showed a left adrenal tumor (diameter, 7 cm) and multiple liver tumors (diameter, ~4 cm) (Figure 1).

The combined examination and investigation results strongly suggested ACC with multiple liver metastases causing primary aldosteronism and subclinical Cushing syndrome. Such cases are classified as clinical stage IV and therefore ineligible for surgery to remove the adrenal tumor. However, the patient hoped to have the adrenal tumor removed, so he requested investigation of the liver tumors to confirm that they had arisen from the ACC.

Adrenal and hepatic venous sampling were carried out. Aldosterone concentration was markedly increased in the left adrenal vein (64,500 μg/dL) but not in the right adrenal or hepatic vein (4870 and 1210 μg/dL, respectively) (Table 3). These findings suggested that the liver tumors were not secreting aldosterone; therefore, biopsies of tissue from both the left adrenal tumor and the liver tumors were carried out to enable pathological diagnosis. Based on the Weiss criteria, the biopsy results for the left adrenal and liver tumors were pathologically consistent with the diagnosis of ACC with hepatic metastasis. Immunohistochemical investigation showed strong positive staining for SF-1, P450c17, P450c21, 3βHSD2, CYP11B1, and CYP11B2 and partial positive staining for P450scC and 3βHSD1 in both the ACC and the liver metastases (Figure 2); these findings indicated synthetic capability for aldosterone and cortisol. The DHEA-ST test result was negative for both the ACC and the liver metastases.

The patient received mitotane (1500 mg/day) but declined combination chemotherapy. Hypoalbuminemia and severe edema of the lung and lower extremities developed rapidly despite administration of high doses of spironolactone, and he died 2 months later.

3. Discussion

To our knowledge, this is the first report of a case of aldosterone-producing ACC with hepatic metastasis in which adrenal and hepatic venous sampling were carried out to assess the production of aldosterone from metastasis of ACC. This was an unusual case because hypersecretion of aldosterone from ACC is rare; in the majority of cases (approximately 60–70%), ACCs present with an excess of adrenal hormone (mostly glucocorticoids or androgens) [1–3].

Although AVS is considered the gold standard test for determining whether the right, left, or both adrenal glands are responsible for the aldosterone excess in cases of primary aldosteronism, to our knowledge, there have been no reports of the use of sampling from the relevant vein to assess aldosterone production from a tumor suspected to have arisen from ACC metastasis. In the case presented in this report, we used hepatic venous sampling to try to help determine whether the liver tumors were ACC metastases or other hepatic tumors (e.g., hepatocellular carcinoma). However, aldosterone concentration in the hepatic veins was not increased, despite the pathological diagnosis of hepatic metastasis of ACC and its synthetic capability for aldosterone.

In cases of insulinoma, hepatic venous sampling after selective intra-arterial injections of calcium into the relevant hepatic artery is carried out to exclude hepatic metastasis of insulinoma [5–8]. In a similar way, liver metastases arising from ACC might be expected to be detected by hepatic venous sampling. Because aldosterone is a lipophilic steroid hormone, it should be released into the blood circulation once synthesized. Our experience in this case suggests that hepatic venous sampling is unsuitable for diagnosis of ACC with hepatic metastasis. Although the liver tumors were found by immunohistochemical investigation to have synthetic capability for aldosterone and cortisol, aldosterone concentration in the hepatic veins was found not to be increased. This might be explained by the limited transportation of aldosterone to the hepatic vein or degradation of aldosterone during its passage through the liver. Further basic research is required to explain this finding.

Adrenocortical carcinoma has a generally poor prognosis, with overall 5-year survival ranging from 60–80% in patients with stage I disease to 13% in those with stage IV. Clinical outcomes vary greatly due to differences in tumor biology, disease presentation, and management options [1, 2, 9, 10]. The results of a recent systematic review and meta-analysis show that cortisol-secreting ACCs are associated with worse overall survival [11]. This higher mortality rate could be explained by negative effects of cortisol on the immune and cardiovascular systems. In cases of aldosterone-secreting ACCs, scarcity of data means that prognosis is uncertain. In the case presented here, the marked hyperaldosteronism could have negatively affected the cardiovascular system and electrolyte balance and thus contributed to the poor outcome.
Table 1: Laboratory findings.

| Blood cell count | Biochemistry   |
|------------------|----------------|
| WBC (μL)         | TP (g/dL)      |
| 6000             | 7.0            |
| Neutrophil (%)   | Alb (g/dL)     |
| 62.2             | 4.2            |
| Lymphocyte (%)   | LDH (IU/L)     |
| 28.3             | 330            |
| Monocyte (%)     | AST (IU/L)     |
| 8.3              | 22             |
| Eosinophil (%)   | ALT (IU/L)     |
| 0.7              | 39             |
| Basophil (%)     | γ-GT (IU/L)    |
| 0.5              | 31             |
| RBC (×10⁶/μL)    | T-Bil (mg/dL)  |
| 4.47             | 0.8            |
| Hemoglobin (g/dL)| ALP (IU/L)     |
| 13.0             | 308            |
| Hematocrit (%)   | Plasma glucose (mg/dL) |
| 38.2             | 95             |
| Platelet (×10⁴/μL) | CRP (mg/dL)  |
| 24.5             | 0.17           |

| Blood cell count | Biochemistry   |
|------------------|----------------|
| RBC (×10⁶/μL)    | T-chol (mg/dL) |
| 4.47             | 167            |
| Hb (g/dL)        | HDL-c (mg/dL)  |
| 13.0             | 60.7           |
| Hematocrit (%)   | LDL-c (mg/dL)  |
| 38.2             | 95.6           |
| Platelet (×10⁴/μL) | TG (mg/dL)  |
| 24.5             | 95             |

Table 2: Endocrinological examination.

| Hormonal profile | Normal range |
|-------------------|--------------|
| Plasma ACTH (pg/mL) | 2.1          | 7.2–63.3   |
| Serum cortisol (μg/dL) | 9.4          | 4.0–18.3   |
| Plasma renin activity (ng/mL/h) | 0.2         | 0.3–2.9    |
| PAC (pg/mL) | 1710          | 140–1030   |
| Serum DHEA-S (μg/dL) | 35           | 12–133     |
| Urinary free cortisol (μg/24h) | 328         | 11.2–80.3  |
| Urinary free aldosterone (μg/24h) | 549         | <10        |

Circadian variation of plasma ACTH and serum cortisol and low-dose (1 mg) DST results

| Time | Plasma ACTH (pg/mL) | Serum cortisol (μg/dL) |
|------|---------------------|------------------------|
| 06:00| <1.0                | 9.8                    |
| 16:00| <1.0                | 11.3                   |
| 23:00| <1.0                | 11.6                   |

1 mg DST

Figure 1: Abdominal computed tomography scan. The red arrow indicates the left adrenal tumor (diameter, 7 cm). The yellow arrows indicate multiple liver tumors (diameter, ~4 cm).
Management of ACC remains challenging due to the heterogeneous and often unpredictable nature of this disease. If our patient’s liver metastases had not produced excessive aldosterone, surgical resection of the primary tumormight have resolved the hyperaldosteronism, and this might have led to a better outcome.

### 4. Conclusion

We report the first case of adrenal and hepatic venous sampling in a patient with aldosterone-producing ACC with hepatic metastasis. Hepatic venous sampling did not detect aldosterone production from the liver tumors.

### Abbreviations

- **3βHSD**: 3β-Hydroxysteroid dehydrogenase
- **ACTH**: Adrenocorticotrophic hormone
- **Alb**: Albumin
- **ALP**: Alkaline phosphatase
- **ALT**: Alanine aminotransferase
- **AST**: Aspartate aminotransferase
- **AST**: Aspartate aminotransferase
- **CK**: Creatine kinase
- **Cr**: Creatinine
- **CRP**: C-reactive protein
- **CYP**: Cytochrome P450
- **DHEA-ST**: Dehydroepiandrosterone sulfotransferase
- **DST**: Dexamethasone suppression test
- **HDL-c**: High-density lipoprotein cholesterol
- **HE**: Hematoxylin and eosin
- **LDH**: Lactase dehydrogenase
- **LDL-c**: Low-density lipoprotein cholesterol
- **P450c17**: Cytochrome P450 17
- **P450c21**: Cytochrome P450 21
- **P450scc**: Cytochrome P450 side-chain cleavage

### Table 3: Adrenal and hepatic venous sampling.

| Sampling point                  | PAC (pg/mL) | Cortisol (µg/dL) | PAC:cortisol ratio |
|--------------------------------|-------------|------------------|------------------|
| **Before ACTH loading**        |             |                  |                  |
| Inferior vena cava             | 3890        | 18.3             | 21.3 × 10⁻³      |
| Left adrenal vein              | 35,000      | 44.7             | 78.3 × 10⁻³      |
| Right adrenal vein             | 3310        | 23.2             | 14.3 × 10⁻³      |
| Hepatic vein                   | 1360        | 18.8             | 7.2 × 10⁻³       |
| **After ACTH loading**         |             |                  |                  |
| Inferior vena cava             | 4260        | 21.4             | 19.9 × 10⁻³      |
| Left adrenal vein              | 64,500      | 58.2             | 110.8 × 10⁻³     |
| Right adrenal vein             | 4870        | 132              | 3.7 × 10⁻³       |
| Hepatic vein                   | 1210        | 21.2             | 5.7 × 10⁻³       |

**Figure 2**: Results of histopathological and immunohistochemical investigation of left adrenal and liver biopsy specimens (magnification, ×200). Microscopic appearance (hematoxylin and eosin, HE, staining) showed eosinophilic tumor cell cytoplasm, nuclear atypia, diffuse architecture, and sinusoidal invasion. Immunohistochemical staining showed strong positive reactivity for SF-1, P450c17, 3βHSD2, P450c21, CYP11B1, and CYP11B2 and partial positive reactivity for P450scc and 3βHSD1 in both the left adrenal tumor (upper panel) and the liver tumor (lower panel). The DHEA-ST test result was negative for both specimens.
PAC: Plasma aldosterone concentration
RBC: Red blood cell
SF-1: Steroidogenic factor 1
T-Bil: Total bilirubin
T-chol: Total cholesterol
TG: Triglycerides
TP: Total protein
UA: Uric acid
UN: Urea nitrogen
WBC: White blood cell
γ-GT: γ-Glutamyltranspeptidase.

Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Ethical Approval
The need for ethical approval and consent to the submission of case reports were waived by the ethics review committee of Japanese Red Cross Musashino Hospital. We followed the principles of the Declaration of Helsinki and paid careful attention to protecting the patient’s identity.

Consent
The patient’s family provided their informed consent to publication of this case report, including the figures.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
TS was the main author to treat this patient and wrote the manuscript. YS cared for the patient when he was admitted to the hospital. HS carried out the pathological and immunohistochemical investigation. EH provided professional opinions regarding the patient’s care and commented on the manuscript. All authors read and approved the final submitted version of the manuscript.

Acknowledgments
The authors would like to thank the Tama Society of Clinical Endocrinology and Metabolism, whose members participated in helpful discussions.

References
[1] T. Else, A. C. Kim, A. Sabolch et al., “Adrenocortical carcinoma,” Endocrine Reviews, vol. 35, no. 2, pp. 282–326, 2014.
[2] M. Fassnacht, M. Kroiss, and B. Alloio, “Update in adrenocortical carcinoma,” The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 12, pp. 4551–4564, 2013.
[3] T. M. Seccia, A. Fassina, G. G. Nussdorfer, A. C. Pessina, and G. P. Rossi, “Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn’s syndrome with an ominous clinical course,” Endocrine-Related Cancer, vol. 12, no. 1, pp. 149–159, 2005.
[4] G. P. Rossi, “Primary aldosteronism,” Journal of the American College of Cardiology, vol. 74, no. 22, pp. 2799–2811, 2019.
[5] J.-M. Guettier, A. Kam, R. Chang et al., “Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience,” The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 4, pp. 1074–1080, 2009.
[6] P. Moreno-Moreno, M. R. Alhambra-Expósito, A. D. Herrera-Martínez et al., “Arterial calcium stimulation with hepatic venous sampling in the localization diagnosis of endogenous hyperinsulinism,” International Journal of Endocrinology, vol. 2016, Article ID 4581094, 6 pages, 2016.
[7] M. Imamura, K. Takahashi, H. Adachi et al., “Usefulness of selective arterial secretin injection test for localization of gastrinoma in the zollinger-ellison syndrome,” Annals of Surgery, vol. 205, no. 3, pp. 230–239, 1987.
[8] P. L. Pereira, A. J. Roche, G. W. Maier et al., “Insulinoma and islet cell hyperplasia: value of the calcium intraarterial stimulation test when findings of other preoperative studies are negative,” Radiology, vol. 206, no. 3, pp. 703–709, 1998.
[9] S. Jasim and M. A. Habra, “Management of adrenocortical carcinoma,” Current Oncology Reports, vol. 21, no. 3, p. 20, 2019.
[10] T. Else, A. R. Williams, A. Sabolch, S. Jolly, B. S. Miller, and G. D. Hammer, “Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 2, pp. 455–461, 2014.
[11] T. Vanbrabant, M. Fassnacht, G. Assie, and O. M. Dekkers, “Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis,” European Journal of Endocrinology, vol. 179, no. 6, pp. 429–436, 2018.